[{"id":"512fe4d7-03cf-43f6-a891-9c37a20aec55","acronym":"","url":"https://clinicaltrials.gov/study/NCT03207529","created_at":"2021-01-18T15:48:40.498Z","updated_at":"2024-07-02T16:35:23.801Z","phase":"Phase 1","brief_title":"Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT03207529","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR • PTEN • AR","pipe":" | ","alterations":" HR positive • HER-2 negative • AR positive • PTEN positive","tags":["HER-2 • ER • PGR • PTEN • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • AR positive • PTEN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-01-11"}]